



Bayer AG
Communications
51368 Leverkusen
Germany
Phone +49 214 30-1
www.bayer.com/en/media

News Release

Guru Ramamurthy appointed as new CFO for Bayer's Crop Science Division

- Effective July 1, 2025, he will succeed Oliver Rittgen who has decided to pursue a career opportunity outside of Bayer after 25 years with the company
 - Guru Ramamurthy has extensive expertise in finance and is currently serving as CFO of Bayer US
-

Monheim, April 29, 2025 – Bayer announced today that Guru Ramamurthy will become the new Chief Financial Officer (CFO) for Bayer's Crop Science division. He will succeed Oliver Rittgen who has decided to pursue a career opportunity outside of Bayer after 25 years with the company. In his current role, Guru Ramamurthy is serving as CFO of Bayer US. The change will become effective as of July 1, 2025. With over 20 years of experience at Bayer, Ramamurthy brings extensive financial expertise and a proven track record in driving transformation and business growth.

Since joining Bayer in 2001, Ramamurthy has held various finance leadership roles across multiple business segments and geographies. Prior to being appointed as the CFO of Bayer US, he served as CFO of AskBio, Bayer's wholly owned and independently operated gene therapy company. Previously, he was the Global CFO of Bayer's Medical Care division and has held country and regional CFO positions across diverse segments. Over the course of his career, he has held key finance roles in Germany, Italy, Japan, and the United States.

"Guru has a strong track record of enabling business turnarounds and driving transformation through a holistic business perspective. His ability to shape business strategies to boost profitability and growth to deliver results, while building high-performing finance teams, has made his leadership stand out. His collaborative and innovative approaches have further amplified his impact. I am looking forward to working

with him to shape the future success of our business,” said Rodrigo Santos, Member of the Board of Bayer AG and President of the company's Crop Science Division.

Guru Ramamurthy will be based in St. Louis, MO. The successor for his current role will be announced at a later date.

Oliver Rittgen joined Bayer in 2000 and served in various leadership roles across Finance. Before assuming the position as CFO for the Crop Science division in 2024, he held the CFO role for Bayer's Consumer Health division. Prior to that, he held several regional CFO and Corporate Finance positions in Germany, Finland, and Thailand.

“Oliver has successfully been driving business performance and transformation across the divisions and has always made it a priority to develop his organization and people at the same time. His innovative and entrepreneurial thinking has helped us to further develop the financial operations of our business. I want to thank him for his valuable contributions and wish him all the best for the future,” added Rodrigo Santos.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Contact for media inquiries:

Germany:

Alexander Hennig, phone +49 175 3089736

Email: alexander.hennig@bayer.com

US:

Brian Leake, phone +1 314 370 3285

Email: brian.leake@bayer.com

ahe (2025-0085e)

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.